Marksans Pharma Beheer

Hoe is Mark Saldanha's beloning veranderd ten opzichte van Marksans Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹3b
Jun 30 2024	n/a	n/a	₹3b
Mar 31 2024	₹69m	₹48m	₹3b
Dec 31 2023	n/a	n/a	₹3b
Sep 30 2023	n/a	n/a	₹3b
Jun 30 2023	n/a	n/a	₹3b
Mar 31 2023	₹52m	₹48m	₹3b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹2b
Jun 30 2022	n/a	n/a	₹2b
Mar 31 2022	₹38m	₹35m	₹2b
Dec 31 2021	n/a	n/a	₹2b
Sep 30 2021	n/a	n/a	₹2b
Jun 30 2021	n/a	n/a	₹3b
Mar 31 2021	₹10m	₹10m	₹2b
Dec 31 2020	n/a	n/a	₹2b
Sep 30 2020	n/a	n/a	₹2b
Jun 30 2020	n/a	n/a	₹1b
Mar 31 2020	₹10m	₹10m	₹1b
Dec 31 2019	n/a	n/a	₹879m
Sep 30 2019	n/a	n/a	₹834m
Jun 30 2019	n/a	n/a	₹780m
Mar 31 2019	₹10m	₹10m	₹804m
Dec 31 2018	n/a	n/a	₹666m
Sep 30 2018	n/a	n/a	₹582m
Jun 30 2018	n/a	n/a	₹463m
Mar 31 2018	₹12m	₹10m	₹358m

Compensatie versus markt: De totale vergoeding ($USD 814.92K ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 503.20K ).

Compensatie versus inkomsten: De vergoeding van Mark is het afgelopen jaar met meer dan 20% gestegen.

CEO

Mark Saldanha (52 yo)

9.1yrs

Tenure

₹68,857,053

Compensatie

Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Saldanha	Non-Independent Executive Chairman & MD	no data	₹68.86m	43.8% ₹ 61.4b
Jitendra Sharma	Chief Financial Officer	22.2yrs	₹12.84m	geen gegevens
Vishal Bhargava	Director Operations	no data	₹5.80m	geen gegevens
Harshavardhan Panigrahi	Company Secretary	15.8yrs	₹2.84m	geen gegevens
Sandra Saldanha	Whole-Time Executive Non Independent Director	10.2yrs	₹7.07m	0.073% ₹ 102.2m
Varddhman Jain	Whole-Time Executive Non Independent Director	5.8yrs	₹18.75m	geen gegevens
Sunil Rane	Senior Vice President of QC	no data	₹10.61m	geen gegevens
David Mohammed	Managing Director of Australia Operations	no data	geen gegevens	geen gegevens
Sathish Kumar	Managing Director of UK Operations	no data	geen gegevens	geen gegevens
Anjani Kumar	Chief Operating Officer of US Operations	no data	₹10.29m	geen gegevens

13.0yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MARKSANS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 13 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Saldanha	Non-Independent Executive Chairman & MD	9.1yrs	₹68.86m	43.8% ₹ 61.4b
Sandra Saldanha	Whole-Time Executive Non Independent Director	10.2yrs	₹7.07m	0.073% ₹ 102.2m
Varddhman Jain	Whole-Time Executive Non Independent Director	5.8yrs	₹18.75m	geen gegevens
Sunny Sharma	Non-Executive & Non-Independent Director	3.3yrs	geen gegevens	geen gegevens
Abhinna Mohanty	Non-Executive & Independent Director	5.3yrs	₹15.00k	geen gegevens
Shailaja Vardhan	Non-Executive & Independent Director	1.5yrs	₹300.00k	geen gegevens
Seetharama Buddharaju	Non-Executive & Independent Director	13.1yrs	₹25.00k	geen gegevens
Digant Parikh	Non-Executive Independent Director	6.7yrs	₹400.00k	geen gegevens

6.3yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MARKSANS wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

Marksans Pharma Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024

Whole-time Director recently bought ₹6.9m worth of stock

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Recent updates

Price target increased by 26% to ₹330

Second quarter 2025 earnings released: EPS: ₹2.13 (vs ₹1.84 in 2Q 2024)

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Marksans Pharma Limited to Report Q2, 2025 Results on Nov 12, 2024

Marksans Pharma Limited Approves Dividend for the Year Ended March 31, 2024

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Upcoming dividend of ₹0.60 per share

Insufficient new directors

Now 21% overvalued after recent price rise

Successful Closure of US FDA Inspection At Marksans Pharma's Manufacturing Facility Located At Verna, Goa

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024

First quarter 2025 earnings released: EPS: ₹1.96 (vs ₹1.52 in 1Q 2024)

Marksans Pharma Limited to Report Q1, 2025 Results on Aug 13, 2024

Now 20% overvalued after recent price rise

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Investor sentiment improves as stock rises 18%

Whole-time Director recently bought ₹6.9m worth of stock

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Full year 2024 earnings: EPS misses analyst expectations

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24

Marksans Pharma Limited to Report Q4, 2024 Results on May 30, 2024

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% overvalued after recent price rise

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Marksans Pharma Limited to Report Q3, 2024 Results on Feb 13, 2024

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹1.84 (vs ₹1.52 in 2Q 2023)

Marksans Pharma Limited to Report Q2, 2024 Results on Nov 09, 2023

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets

Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23

Full year 2023 earnings released: EPS: ₹6.39 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Investor sentiment improves as stock rises 16%

Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg

Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023

Full year 2023 earnings released: EPS: ₹6.41 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: EPS: ₹1.56 (vs ₹1.20 in 3Q 2022)

Marksans Pharma Limited to Report Q3, 2023 Results on Feb 13, 2023

Marksans Pharma Limited announced that it has received funding from OrbiMed Asia IV Mauritius FVCI Limited

Second quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.11 in 2Q 2022)

Marksans Pharma Limited to Report Q2, 2023 Results on Nov 14, 2022

Marksans Pharma Limited (BSE:524404) entered into a Business Transfer Agreement to acquire Bulk Pharmaceutical Business of Tevapharm India Private Limited.

Marksans Pharma Limited Declares Dividend, Payable on or After 20 September 2022

Upcoming dividend of ₹0.25 per share

Full year 2022 earnings released: EPS: ₹4.56 (vs ₹5.83 in FY 2021)

Marksans Pharma Limited to Report Q1, 2023 Results on Aug 13, 2022

Marksans Pharma Limited, Annual General Meeting, Aug 29, 2022

Marksans Pharma Limited Announces US FDA Approval for Pregabalin Capsules

Marksans Pharma Limited (BSE:524404) announces an Equity Buyback for INR 600 million worth of its shares.

Investor sentiment improved over the past week

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Marksans Pharma Limited (BSE:524404) completed the acquisition of Access Healthcare for Medical Products LLC.

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Fiscal Year 2022 Results on May 30, 2022

Marksans Pharma Limited (BSE:524404) has signed agreement to acquire share capital of Access Healthcare for Medical Products LLC for AED 13 million.

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Q3, 2022 Results on Feb 11, 2022

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)